AlphaMadera
Disc Medicine, Inc. (IRON)
$85.33
-1.75 (-2.01%)Delayed quote.
Price history
Daily close- Start
- $86.02
- Latest close
- $87.08
- Period change
- +1.23%
- Period low
- $55.74
- Period high
- $94.11
Key metrics
- Market cap
- $3.28B
- Volume
- 49.9K
- Average volume
- 755.0K
- 52-week range
- $40.00 – $99.50
- Beta
- 2.01
- Last dividend
- —
- EPS (TTM)
- -$6.36
- P/E ratio
- -13.21
- Revenue (TTM)
- $0
- Net income (TTM)
- -$243.10M
- Total assets
- $699.49M
- Total debt
- $61.09M
- Cash and equivalents
- $89.98M
Key financials (trailing twelve months).
Company profile
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- CEO
- John D. Quisel
- Employees
- 165
- Headquarters
- Watertown, MA, US
- IPO date
- 2020-08-12
- Website
- https://www.discmedicine.com
Financial statements
Annual, last 3 fiscal years. Most recent period first. Reported in USD.
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 |
| Operating income | -$236.02M | -$129.72M | -$91.12M |
| EBITDA | -$207.94M | -$108.27M | -$76.23M |
| Net income | -$212.18M | -$109.36M | -$76.43M |
| Diluted EPS | -$6.01 | -$3.96 | -$3.42 |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $91.14M | $192.43M | $360.38M |
| Total assets | $806.88M | $496.77M | $368.00M |
| Total liabilities | $67.05M | $53.19M | $22.88M |
| Total debt | $1.86M | $30.00M | $2.10M |
| Shareholders’ equity | $739.83M | $443.59M | $345.12M |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$180.39M | -$93.93M | -$73.46M |
| Capital expenditure | -$933.0K | -$505.0K | -$89.0K |
| Free cash flow | -$181.33M | -$94.43M | -$73.55M |
Quarterly, last 6 quarters. Most recent period first. Reported in USD.
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$64.16M | -$65.08M | -$69.52M | -$66.97M | -$67.70M | -$61.41M |
| EBITDA | -$57.62M | -$58.47M | -$62.52M | -$59.47M | -$61.22M | -$54.20M |
| Net income | -$59.53M | -$59.53M | -$63.50M | -$60.53M | -$62.32M | -$55.25M |
| Diluted EPS | -$1.53 | -$1.54 | -$1.65 | -$1.64 | -$1.77 | -$1.58 |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $89.98M | $98.68M | $88.91M | $91.14M | $140.66M | $127.34M |
| Total assets | $699.49M | $735.07M | $750.21M | $806.88M | $630.46M | $665.06M |
| Total liabilities | $95.24M | $90.91M | $61.78M | $67.05M | $57.07M | $50.90M |
| Total debt | $61.09M | $60.86M | $31.06M | $1.86M | $30.98M | $30.92M |
| Shareholders’ equity | $604.25M | $644.16M | $688.43M | $739.83M | $573.39M | $614.16M |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$40.20M | -$44.20M | -$62.24M | -$43.30M | -$47.80M | -$47.92M |
| Capital expenditure | $0 | $0 | $0 | -$20.0K | -$26.0K | -$36.0K |
| Free cash flow | -$40.20M | -$44.20M | -$62.24M | -$43.32M | -$47.83M | -$47.95M |